The weight loss drug is so profitable that its parent company, Danish health care giant Novo Nordisk, is propping up Denmark’s entire economy. It’s poised to transform America’s too.
This episode was produced by Victoria Chamberlin edited by Jolie Myers, fact-checked by Kim Eggleston, engineered by Rob Byers, and hosted by Noel King.
Transcript at vox.com/to ... Show More
Sep 12
Your midterms study guide
With the 2026 midterms fast approaching, we’re asking a simple question: What actually matters to voters right now? This show was edited by Kasia Broussalian, fact checked by Esther Gim, mixed by Shannon Mahoney, video edited by Christopher Snyder, and hosted by Astead Herndon. A ... Show More
32m 21s
Jun 2024
The weight-loss drug revolution
Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show More
17m 28s
Jun 2024
Denmark and the Novo Nordisk effect
<p>In the first of a two-part series, in collaboration with The Food Chain, we look at the impact of the success of weight-loss drug manufacturer Novo Nordisk on the small country of Denmark. </p><p>The Scandinavian nation is where the company is based, and with a population of l ... Show More
17m 29s
Dec 2024
Deep Dive: The Gold Rush to Cure the Obesity Epidemic
<p>GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapid ... Show More
8m 47s